SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Preventive Visit — Lorraine Hansberry — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLorraine Hansberry
Date of birth1930-05-19
IdentifiersMRN HR-ML034-SYN-TD; SSN (made up) 000-34-7158
Document date1963-10-21
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit, on day 10 of the first cycle of chemotherapy after surgery. [S]

History of Present Illness

Ms. Hansberry, now 33, comes for her yearly preventive visit on day 10 of the first cycle of fluorouracil, leucovorin and irinotecan after her pancreaticoduodenectomy. The cycle went well: one day of nausea settled with olanzapine, two loose stools on day 4 controlled with loperamide, and no fever. She takes pancrelipase three capsules with meals and two with snacks, and her stools are formed. Insulin glargine is 10 units at night; fasting readings are 110 to 140 mg/dL with no low readings. She takes apixaban twice a day without bleeding. The tingling in her fingers in the cold is fading now that oxaliplatin has stopped. She writes most mornings and has finished a draft of the new play's second act. Her PHQ-9 today is 5. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 33
Active conditionsPancreatic adenocarcinoma after six cycles of modified FOLFIRINOX and pancreaticoduodenectomy (R0); on chemotherapy after surgery; diabetes due to pancreatic disease on insulin; exocrine pancreatic insufficiency on pancrelipase
MedicinesFluorouracil, leucovorin and irinotecan every two weeks; pegfilgrastim; apixaban 2.5 mg twice daily; insulin glargine 10 units; pancrelipase; pantoprazole; olanzapine, ondansetron and loperamide as needed; oxycodone rarely
MoodPHQ-9 5

Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchetti-Fields. [S]

DomainFinding
Self-rated healthFair, and better than before surgery
PsychosocialClose friends and fellow writers visit and drive her to treatment; worry about the cancer returning; writing gives her purpose
TobaccoNever smoked
Alcohol and drugsNo alcohol since diagnosis; no drugs
Physical activityWalks 20 minutes by the river most days
NutritionFive small meals a day with pancrelipase; weight steady since surgery; follows the dietitian's plan
SleepSeven hours, broken on the nights after chemotherapy
Sexual and reproductive healthNot sexually active now; would use condoms and talk to the clinic first; does not want a pregnancy during or soon after treatment
Safety at homeFeels safe; no one hurts, threatens, or controls her; no firearm in the home
Road safetyWears a seat belt; friends drive her on treatment days
Activities of daily livingIndependent

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired for two days after each cycle; no fever, night sweats or weight loss since surgery
EyesNegativeNo vision change; dilated eye examination last week normal
Ears, nose, mouth, and throatNegativeNo mouth sores
CardiovascularNegativeNo chest pain or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalPositiveNausea for one day and two loose stools after the cycle; stools otherwise formed; no abdominal pain or yellow eyes
GenitourinaryNegativeNo urinary symptoms; periods irregular since chemotherapy
BreastNegativeNo lump or nipple discharge
MusculoskeletalNegativeNo joint or bone pain
IntegumentaryNegativeHair thinning; incision healed
NeurologicalPositiveTingling in the fingertips in the cold, fading
EndocrineNegativeNo low glucose readings
Hematologic and lymphaticNegativeNo bruising or bleeding on apixaban
PsychiatricNegativeMood fair; PHQ-9 5; no thoughts of self-harm

14 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route1963-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route1963-04-24 to 1963-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route1963-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route1963-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route1963-05-04 to 1963-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route1963-05-18 to 1963-07-13completedS
Irinotecan 20 mg/mL injection, 190 mg (120 mg/m2, one dose level lower) intravenously on day 1 of cycle 6Day 1 of cycle 6Intravenous route1963-07-27 to 1963-07-27completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route1963-05-18 to 1963-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route1963-05-20 to 1963-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route1963-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route1963-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route1963-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route1963-06-29 to 1963-08-21completedS
Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days40 mEq today, then 20 mEq daily for three daysOral route1963-07-16 to 1963-07-19completedS
Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery40 mg once daily for 28 daysSubcutaneous route1963-08-24 to 1963-09-21completedS
Insulin glargine 100 units/mL pen, 8 units under the skin at night8 units at nightSubcutaneous route1963-08-28 to 1963-10-05completedS
Insulin glargine 100 units/mL pen, 10 units under the skin at night10 units at nightSubcutaneous route1963-10-05activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snackThree capsules with each meal, two with each snackOral route1963-10-05activeS
Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgeryDay 1 every 14 days for six cyclesIntravenous route1963-10-12activeS
Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgeryDay 1 every 14 days for six cyclesIntravenous route1963-10-12activeS
Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery46-hour infusion from day 1 every 14 days for six cyclesIntravenous route1963-10-12activeS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery6 mg on day 3 of each cycleSubcutaneous route1963-10-14activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgeryOne tablet twice dailyOral route1963-10-12activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1963-10-21Body height163cmS
1963-10-21Body weight52.4kgS
1963-10-21Body mass index (BMI) [Ratio]19.7kg/m2S
1963-10-21Systolic blood pressure106mm[Hg]S
1963-10-21Diastolic blood pressure66mm[Hg]S
1963-10-21Heart rate84/minS
1963-10-21Respiratory rate14/minS
1963-10-21Body temperature36.6CelS
1963-10-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1963-10-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 1963-10-21; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 52.4 kg, BMI 19.7; blood pressure 106/66
Head, eyes, ears, nose, and throatNo mouth sores; no scleral icterus
NeckNo lymph nodes; thyroid normal
BreastsExamined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes
CardiovascularRegular rhythm; no murmur; no leg swelling
RespiratoryClear to auscultation bilaterally
AbdomenHealed upper midline and right subcostal incision; soft, non-tender; no mass, no fluid
SkinPort site clean; no rash or bruising
FeetMonofilament sensation normal; pulses present; no lesions
NeurologicalLight touch slightly reduced at the fingertips; vibration and reflexes normal; steady gait
PsychiatricThoughtful, wry and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPresolvedconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolvedresolvedconfirmed K52.1S — Synthetic treatment effect; not a historical claim.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.
After pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection: loss of the head of the pancreas, with more marked exocrine insufficiency and insulin-requiring diabetesactiveconfirmed Z90.411S — Synthetic consequence of the synthetic operation.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today106/66 mmHg
Depression screeningCompleted todayPHQ-9 score 5; item 9 scored 0
Unhealthy alcohol use screeningCompleted todayNo alcohol since diagnosis
Tobacco useCompleted todayNever smoked
Intimate partner violence screeningCompleted todayNegative; she feels safe
Cervical cancer screeningDueDue (last test four years ago, normal); HPV test planned after chemotherapy ends, at her choice
Breast cancer screeningNot indicatedScreening mammography starts at 40; no family history of breast or ovarian cancer; germline panel negative
Colorectal cancer screeningNot indicatedStarts at 45; germline panel negative for Lynch syndrome genes
HIV, hepatitis B and hepatitis C screeningUp to dateAll negative before chemotherapy; hepatitis B surface antibody negative
Diabetes care: A1c, eye and foot examination, urine albuminUp to dateA1c 7.0% in August; dilated eye examination last week normal; foot examination today normal; urine albumin-to-creatinine ratio normal at the visit after surgery
Lipid screeningDueRecommended for adults with diabetes; with the next blood tests
Influenza vaccineCompleted todayInactivated vaccine given between cycles
COVID-19 vaccineCompleted todayThis season's mRNA vaccine given
Pneumococcal vaccineUp to datePCV20 before chemotherapy
Recombinant zoster vaccineUp to dateTwo doses, before and during chemotherapy, for an adult on immunosuppressive treatment
Hepatitis B vaccineDueSurface antibody negative; series after chemotherapy ends
Tetanus, diphtheria, and pertussisUp to dateTdap four years ago
Live vaccines (MMR, varicella)Not indicatedImmune from childhood doses; live vaccines are avoided during chemotherapy
Contraception counselingCompleted todayNo estrogen because of clot risk; condoms for now; IUD offered for later
Dental examinationDueCleaning between cycles when counts are recovered

Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula [S]

Guideline basis: Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Cycle 2 in five days. Cervical screening and the hepatitis B vaccine series after chemotherapy. Next preventive visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, building on her conversations with the palliative care team. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care proxy form. She said that she wants to be told everything about her illness directly and in plain words, never through someone else; that she wants all treatment that has a real chance of controlling the cancer, as long as she can think clearly and write; and that if the cancer returns and can no longer be controlled, she would want care focused on comfort and on time at her desk and with her friends, at home if possible, rather than intensive care. She asked that her pain be treated fully even if it makes her sleepier near the end. To be revisited at each change in her health and at least yearly. [S]